Cardiovascular Risk Factors Undertreated in Veterans With Prostate Cancer
In a study, 1 in 4 male veterans with prostate cancer failed to receive a comprehensive assessment of their cardiovascular risk factors.
Androgen-deprivation Therapy
Adding a First-Generation Anti-Androgen to ADT for mCSPC Does Not Improve Outcomes
Real-world data show that a combination of a first-generation anti-androgen drug and androgen deprivation therapy is no better than ADT alone in improving outcomes among men with metastatic castration-sensitive prostate cancer.
Percent Decline in PSA May Predict Survival in Enzalutamide-Treated nmCRPC
The percent decline and actual decline in PSA levels in men with nonmetastatic castration-resistant prostate cancer treated with androgen deprivation therapy and enzalutamide are associated with the risk for death and metastasis, a study found.
Optimal Sequencing of ADT and RT for Low PSA Prostate Cancer Probed
During the COVID-19 pandemic, neoadjuvant ADT has been used as a way to delay initiation of daily radiation therapy, but it may not be appropriate for all men.
Prostate Cancer Hormone Therapy May Not Protect Against COVID-19 Virus
In a recent cohort study, the risk for COVID-19 infection did not differ significantly between ADT users and nonusers.
Adding Enzalutamide to Radium-223 Does Not Up Survival in Advanced mCRPC
For the third-line treatment of men with bone-dominant metastatic castration-resistant prostate cancer, enzalutamide plus radium-223 does not significantly improve overall survival compared with radium-223 alone, a study found.
Study May Clarify Which Systemic Drugs Offer Best Survival in mCSPC
A meta-analysis suggests that abiraterone or apalutamide added to androgen deprivation therapy for men with metastatic castration-sensitive prostate cancer offers the best overall survival.
Statins May Benefit Patients Receiving ADT for Relapsed Prostate Cancer
In a study, statin use was associated with a 36% decreased risk for death among men initiating androgen deprivation therapy for recurrent prostate cancer following primary or salvage radiation therapy.
Darolutamide Prolongs Overall Survival in nmCRPC
Darolutamide also improved secondary endpoints, including the time to pain progression, cytotoxic chemotherapy, and first symptomatic skeletal event.
Oral Antiandrogens Found to Increase Dementia Risk
In a study, only androgen deprivation therapy with oral antiandrogens were associated with an increased risk for dementia and Alzheimer disease.
-
Loading...
-
Loading...
Next post in Prostate Cancer
